Analysis of Vaccine Effectiveness Against COVID-19 and the Emergence of Delta and Other Variants of Concern in Utah | Vaccination | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Analysis of Vaccine Effectiveness Against COVID-19 and the Emergence of Delta and Other Variants of Concern in Utah

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Since the emergence of SARS-CoV-2, vaccines have been heralded as the best way to curtail the COVID-19 pandemic. Clinical trials have shown SARS-CoV-2 vaccines to be highly efficacious against both disease and infection.1 However, those vaccines currently in use were primarily tested against early lineages. Data on vaccine effectiveness against variants of concern (VOCs) remains limited, including the Delta variant (B.1.617.2).

Sign in to take quiz and track your certificates

Buy This Activity

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: November 1, 2021.

Published: December 23, 2021. doi:10.1001/jamanetworkopen.2021.40906

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Keegan LT et al. JAMA Network Open.

Corresponding Author: Lindsay T. Keegan, PhD, Division of Epidemiology, Internal Medicine, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108 (lindsay.keegan@utah.edu).

Author Contributions: Drs Keegan and Lessler had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Keegan, Truelove.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: All authors.

Obtained funding: Keegan.

Administrative, technical, or material support: Keegan.

Conflict of Interest Disclosures: Dr Keegan reported receiving grants from the National Institutes of Health (NIH) and receiving research contracts from Pfizer and Becton Dickinson Research outside the submitted work. Dr Lessler reported receiving grants from the NIH and the US Department of Health and Human Services and serving as an expert witness for Cohen Ziffer Frenchman and McKenna on cases related to COVID-19 outside the submitted work. Dr Truelove reported consulting on SARS-CoV-2 transmission, modeling, and projected impacts outside the submitted work. No other disclosures were reported.

Funding/Support: Dr Keegan was supported by grant 5U01CK000585-02 and 5U01CK000555-02 from the Centers for Disease Control and Prevention. Dr Truelove was supported by a National Science Foundation COVID-19 RAPID award. Drs Truelove and Lessler were supported by grants from the US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response to the Johns Hopkins Applied Physics Laboratory.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the Utah Department of Health for their tireless efforts to collect and share data on SARS-CoV-2 infection, vaccination, and sequencing.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
2.
Kingsley P. Israel, a World Leader in Fighting the Virus, Grapples With a New Outbreak. New York Times. 2021. Accessed November 16, 2021. https://www.nytimes.com/2021/06/24/world/middleeast/israel-covid-delta-variant.html
3.
Bernal  JL , Andrews  N , Gower  C ,  et al.  Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.   medRxiv. 2021;2021.05.22.21257658. doi:10.1101/2021.05.22.21257658Google Scholar
4.
Overview of COVID-19 surveillance. Utah Department of Health. 2021. Accessed November 16, 2021. https://coronavirus.utah.gov/case-counts/
5.
Orenstein  WA , Bernier  RH , Dondero  TJ ,  et al.  Field evaluation of vaccine efficacy.   Bull World Health Organ. 1985;63(6):1055-1068.PubMedGoogle Scholar
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close